RAPP options turn defensive as analyst targets leap above $29 stock

Rapport Therapeutics heads into its November 6 earnings report with a striking disconnect: the stock trades near $29, down 27% over the past month, while analysts have spent this week sharply lifting price targets to levels well above $60.

Options traders are the most cautious they have been in months. The put/call ratio has climbed to 1.31, more than two standard deviations above its 20-day average of 0.89. That makes the current reading the most defensively skewed it has been since mid-year. The shift is not subtle: for most of September, the PCR held in the 0.74 to 0.83 range. Since early October it has broken cleanly above 1.0, suggesting investors are actively buying downside protection ahead of the print rather than positioning for a recovery.

Short interest tells a calmer story. Bears hold about 6.7% of the free float, up 48% over the past month in share count terms but still not at an extreme level. More telling is how little pressure exists on the borrow side: availability stands at over 1,100% of short interest, far above last year's tightest reading of 412%, meaning there is ample room for new shorts to enter. Cost to borrow is negligible at 0.40%, down 14% on the week. This is a stock where incremental bearish positioning is cheap and easy, yet utilisation remains very low. Short sellers appear to be watching rather than crowding in.

The analyst community is doing the opposite. At least five separate firms moved targets higher or initiated coverage this week alone. Jones Trading lifted its target from $50 to $82, while BTIG raised to $89 from $75 on Tuesday. Guggenheim moved to $70 from $65. UBS and Wolfe Research both initiated fresh Buy or Outperform ratings last week with targets in the $50 to $71 range. Wells Fargo trimmed marginally to $50 but kept its Overweight. The consensus target now sits near $69, against a stock trading at $29.37. That implied return is one of the widest in the small-cap biotech universe, and RAPP ranks in the 99th percentile on analyst recommendation divergence in the ORTEX factor score universe. The bull case, built around RAP-219's phase 2a focal-onset seizure data showing a 77.8% median seizure reduction, gives bulls confidence in the phase 3 programme. The bear case focuses on the mania indication as an as-yet unproven thesis and notes that the stock fell from above $52 to below $35 on what was supposed to be optionality, not a core value driver.

One item worth noting on the register: a Schedule 13D/A was filed last year by Dr. James I. Healy at 4.2% of shares. A 13D signals activist intent rather than passive holding, and while this filing is dated September 2025, it remains the most recent disclosure from that holder. Stakes are as last disclosed around the 5% threshold, and a holder dropping below 5% may exit without a further filing. Separately, Third Rock Ventures remains the largest holder at 15.1% of shares, and Cormorant Asset Management trimmed 300,000 shares in the most recently reported period. Among the passive names, BlackRock added 194,000 shares in the period to September 30.

The past four earnings prints have produced mixed reactions. The stock gained roughly 10% on the day after the August 5 result and held most of that over five days. Before that, the two prior prints produced one-day moves of minus 4% and minus 1.8%. The November 6 report lands 16 days from now, with no alt-data leading indicator measured against RAPP's figures: the only dataset showing an unusual signal is Wikipedia and ORTEX page views, which spiked to a z-score of 6.2 in late September, a marker of elevated retail attention rather than a revenue indicator.

What to watch into November 6: whether the gap between analyst targets in the $50 to $89 range and the $29 stock price narrows on company-driven news, or whether the defensive options positioning proves well-founded at the print.